Catalyst

Slingshot members are tracking this event:

Pfizer's (PFE) IBRANCE + Endocrine Therapy for HR+/HER2- Metastatic Breast Cancer Recommended for Approval by European Ad Comm

Source Link:
http://www.pfizer.com/news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_ibrance_palbociclib_in_combination_with_endocrine_therapy_for_the_treatment_of_hr_her2_metastatic_breast_cancer_in_europe

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
PFE
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Sep 16, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Hr+/her2- Metastatic Breast Cancer, Ibrance, Endocrine Therapy, Chmp, European Medicines Agency
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.